| Company Name: |
AntibodySystem
|
| Tel: |
027-65279366 18162686757 |
| Email: |
biolab-reagents@atagenix.com |
| Products Intro: |
Product Name:Research Grade Brodalumab(DHJ38901)
CAS:1174395-19-7
Purity:PAGE:>95% Package:100ug;1mg
|
|
| | Brodalumab Basic information |
| Product Name: | Brodalumab | | Synonyms: | Brodalumab;Research Grade Brodalumab(DHJ38901);Brodalumab (anti-IL17RA) | | CAS: | 1174395-19-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Brodalumab Structure]() |
| | Brodalumab Chemical Properties |
| storage temp. | Store at -20°C |
| | Brodalumab Usage And Synthesis |
| Uses | Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis. | | Clinical Use | Human monoclonal immunoglobulin IgG2 antibody:
Treatment of moderate to severe plaque psoriasis | | Drug interactions | Potentially hazardous interactions with other drugs
Avoid with live vaccines. | | Metabolism | Brodalumab is expected to be degraded into small
peptides and amino acids via catabolic pathways in a
manner similar to endogenous IgG.
Brodalumab is expected to be mainly eliminated via
catabolism and hepatic impairment is not expected to
influence clearance. |
| | Brodalumab Preparation Products And Raw materials |
|